The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Glucagon-Like Peptide-1 Gene Therapy in Obese Diabetic Mice Results in Long-Term Cure of Diabetes by Improving Insulin Sensitivity and Reducing Hepatic Gluconeogenesis
Abstract
Long-term treatment with glucagon-like peptide (GLP)-1 or its analog can improve insulin sensitivity. However, continuous administration is required due to its short half-life. We hypothesized that continuous production of therapeutic levels of GLP-1 in vivo by a gene therapy strategy may remit hyperglycemia and maintain prolonged normoglycemia. We produced a recombinant adenovirus expressing GLP-1 (rAd-GLP-1) under the cytomegalovirus promoter, intravenously injected it into diabetic ob/ob mice, and investigated the effect of this treatment on remission of diabetes, as well as the mechanisms involved. rAd-GLP-1–treated diabetic ob/ob mice became normoglycemic 4 days after treatment, remained normoglycemic over 60 days, and had reduced body weight gain. Glucose tolerance tests found that exogenous glucose was cleared normally. rAd-GLP-1–treated diabetic ob/ob mice showed improved β-cell function, evidenced by glucose-responsive insulin release, and increased insulin sensitivity, evidenced by improved insulin tolerance and increased insulin-stimulated glucose uptake in adipocytes. rAd-GLP-1 treatment increased basal levels of insulin receptor substrate (IRS)-1 in the liver and activation of IRS-1 and protein kinase C by insulin in liver and muscle; increased Akt activation was only observed in muscle. rAd-GLP-1 treatment reduced hepatic glucose production and hepatic expression of phosphoenolpyruvate carboxykinase, glucose-6-phosphatase, and fatty acid synthase in ob/ob mice. Taken together, these results show that a single administration of rAd-GLP-1 results in the long-term remission of diabetes in ob/ob mice by improving insulin sensitivity through restoration of insulin signaling and reducing hepatic gluconeogenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Its main roles are the stimulation of insulin release [30], suppression of glucagon secretion [31], delay of gastric emptying and reduction in food intake [32].”
From The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update. (2024) · cites this paper as [32]
In the citing paper
“Metabolic effects mediated by GLP-1 include increased glucose uptake and glycogen production in skeletal muscle, as well as inhibition of gluconeogenesis in the liver [38]”
From New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists (2024) · cites this paper as [38]
Citations
Cites
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovich, M., & Hemmings, B. A. (1995) · Nature · doi:10.1038/378785a0 · Cited by 5,244
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 3×
“In type 2 diabetic patients, subcutaneous infusion of GLP-1 for 6 weeks resulted in improved insulin sensitivity and -cell function (6).”
BackgroundResultKohn, A. D., Summers, S. A., Birnbaum, M. J., & Roth, R. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.49.31372 · Cited by 1,284
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Kieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062
Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling
SHEPHERD, P. R., WITHERS, D. J., & SIDDLE, K. (1998) · Biochemical Journal · doi:10.1042/bj3330471 · Cited by 953
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
Magnusson, I., Rothman, D. L., Katz, L. D., Shulman, R. G., & Shulman, G. I. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115997 · Cited by 757 · cited 1×
“Elevated hepatic glucose production, due to increased gluconeogenesis, glycogenolysis, or both, is associated with the pathogenesis of type 2 diabetes (38,39).”
Background
Cited by
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
“…show that injection of a recombinant adenovirus expressing GLP-1 into obese diabetic mice increases insulin-stimulated glucose uptake in adipocytes (Lee et al., 2007), and GLP-1 also augments insulin-stimulated glucose uptake along with an increase in glucose transporter levels in 3T3-L1…”
BackgroundGlucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
Armstrong, M. J., Hull, D., Guo, K., Barton, D., Hazlehurst, J. M., Gathercole, L. L., Nasiri, M., Yu, J., Gough, S. C., Newsome, P. N., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.08.038 · Cited by 456
Svegliati‐Baroni, G., Saccomanno, S., Rychlicki, C., Agostinelli, L., De Minicis, S., Candelaresi, C., Faraci, G., Pacetti, D., Vivarelli, M., Nicolini, D., et al. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02462.x · Cited by 405
Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase
Ben-Shlomo, S., Zvibel, I., Shnell, M., Shlomai, A., Chepurko, E., Halpern, Z., Barzilai, N., Oren, R., & Fishman, S. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.09.032 · Cited by 328
Lee, Y.-S., Park, M.-S., Choung, J.-S., Kim, S.-S., Oh, H.-H., Choi, C.-S., Ha, S.-Y., Kang, Y., Kim, Y., & Jun, H.-S. (2012) · Diabetologia · doi:10.1007/s00125-012-2592-3 · Cited by 319
Self-citationChambers, A. P., Jessen, L., Ryan, K. K., Sisley, S., Wilson–Pérez, H. E., Stefater, M. A., Gaitonde, S. G., Sorrell, J. E., Toure, M., Berger, J., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.05.050 · Cited by 289
Shirakawa, J., Fujii, H., Ohnuma, K., Sato, K., Ito, Y., Kaji, M., Sakamoto, E., Koganei, M., Sasaki, H., Nagashima, Y., et al. (2011) · Diabetes · doi:10.2337/db10-1338 · Cited by 246
Anti-obesity therapy: from rainbow pills to polyagonists
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199
Glucagon-like peptide-1 analogues: An overview
Gupta, V. (2013) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.111625 · Cited by 186
“It has shown to reduce insulin resistance locally at the level of beta‐cell and fat cell (reduced release of free fatty acids) and systemically (down‐gradation of markers of inflammation).[41,44]”
BackgroundShimoda, M., Kanda, Y., Hamamoto, S., Tawaramoto, K., Hashiramoto, M., Matsuki, M., & Kaku, K. (2011) · Diabetologia · doi:10.1007/s00125-011-2069-9 · Cited by 161
Nobili, V., Carpino, G., Alisi, A., Franchitto, A., Alpini, G. D., Vito, R. D., Onori, P., Alvaro, D., & Gaudio, E. (2012) · Hepatology · doi:10.1002/hep.25742 · Cited by 160
Liu, X., Zhang, Y., Zheng, S., Lin, R., Xie, Y., Chen, H., Zheng, Y., Liu, E., Chen, L., Yan, J., et al. (2017) · Clinical Endocrinology · doi:10.1111/cen.13454 · Cited by 165
Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis
Tomás, E., & Habener, J. F. (2009) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2009.11.007 · Cited by 139
Sharma, D., Tekade, R. K., & Kalia, K. (2020) · Phytomedicine · doi:10.1016/j.phymed.2020.153235 · Cited by 132
Ligumsky, H., Wolf, I., Israeli, S., Haimsohn, M., Ferber, S., Karasik, A., Kaufman, B., & Rubinek, T. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1585-0 · Cited by 121
Glucagon-Like Peptide 1 Increases β-Cell Regeneration by Promoting α- to β-Cell Transdifferentiation
Lee, Y.-S., Lee, C., Choung, J.-S., Jung, H.-S., & Jun, H.-S. (2018) · Diabetes · doi:10.2337/db18-0155 · Cited by 122
Self-citationTherapy in the Early Stage: Incretins
Cernea, S., & Raz, I. (2011) · Diabetes Care · doi:10.2337/dc11-s223 · Cited by 123
Antidiabetic effect of a newly identified component of Opuntia dillenii polysaccharides
Zhao, L., Lan, Q. J., Huang, Z., Ouyang, L., & Zeng, F. H. (2011) · Phytomedicine · doi:10.1016/j.phymed.2011.01.001 · Cited by 109
Wang, T. T., Hu, S. Y., Hai‐dong, G., Zhang, G. Y., Liu, C. Z., Feng, J. B., & Frezza, E. E. (2008) · Annals of Surgery · doi:10.1097/sla.0b013e318172504d · Cited by 110
GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease
Lee, J., Hong, S.-W., Rhee, E.-J., & Lee, W.-Y. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.4.262 · Cited by 87
Jean, M., Alameh, M., Jesus, D. D., Thibault, M., Lavertu, M., Darras, V., Nelea, M. I., Buschmann, M. D., & Merzouki, A. (2011) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2011.10.029 · Cited by 85
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Cahen, D. L., & van Raalte, D. H. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12593 · Cited by 74
Kapodistria, K., Tsilibary, E.-P. C., Kotsopoulou, E. S., Moustardas, P., & Kitsiou, P. V. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13259 · Cited by 75
Zhou, J. Y., Poudel, A., Welchko, R. M., Mekala, N. K., Chandramani-Shivalingappa, P., Rosca, M. G., & Li, L. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172594 · Cited by 74
Mudaliar, S. R. D., & Henry, R. R. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.12.006 · Cited by 73
GLP ‐1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c‐ JNK
Zhang, L., Yang, M., Ren, H., Hu, H., Boden, G. H., Li, L., & Yang, G. (2013) · Liver International · doi:10.1111/liv.12120 · Cited by 67
Peptide‐based multi‐agonists: a new paradigm in metabolic pharmacology
Brandt, S. J., Müller, T. D., DiMarchi, R. D., Tschöp, M., & Stemmer, K. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12837 · Cited by 71
Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus
Kennedy, L., & Freeman, J. S. (2009) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.76.s5.03 · Cited by 74
Gandoy-Fieiras, N., González‐Juanatey, J. R., & Eirás, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072641 · Cited by 71
Nonalcoholic fatty liver disease and atherosclerosis
Gaudio, E., Nobili, V., Franchitto, A., Onori, P., & Carpino, G. (2012) · Internal and Emergency Medicine · doi:10.1007/s11739-012-0826-5 · Cited by 67
Jean, M., Alameh, M., Buschmann, M. D., & Merzouki, A. (2011) · Gene Therapy · doi:10.1038/gt.2011.25 · Cited by 69
Yang, M., Ma, X., Xuan, X., Deng, H., Chen, Q., & Li, Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00432 · Cited by 61
Non-Alcoholic Fatty Liver Disease: Is Bariatric Surgery the Answer?
Pillai, A. A., & Rinella, M. E. (2009) · Clinics in Liver Disease · doi:10.1016/j.cld.2009.07.012 · Cited by 63
Habener, J. F., & Stanojevic, V. (2012) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2012.10.009 · Cited by 61
Exendin-4 attenuates endoplasmic reticulum stress through a SIRT1-dependent mechanism
Lee, J., Hong, S., Park, S. E., Rhee, E., Park, C., Oh, K.-W., Park, S. W., & Lee, W. (2014) · Cell Stress and Chaperones · doi:10.1007/s12192-013-0490-3 · Cited by 57
Forst, T. M., Uhlig‐Laske, B., Ring, A., Ritzhaupt, A., Graefe‐Mody, U., & Dugi, K. A. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01386.x · Cited by 64
Regulation of bile acid metabolism-related signaling pathways by gut microbiota in diseases
Jia, E., Liu, Z.-Y., Pan, M., Lu, J., & Ge, Q. (2019) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b1900073 · Cited by 56
Samson, S. L., Gonzalez, E. V., Yechoor, V., Bajaj, M., Oka, K., & Chan, L. (2008) · Molecular Therapy · doi:10.1038/mt.2008.198 · Cited by 54
Hsieh, Y.-L., Yao, H., Cheng, R., & Chiang, M. (2012) · Journal of Medicinal Food · doi:10.1089/jmf.2011.1882 · Cited by 52
Kim, M.-H., Kim, E.-H., Jung, H. S., Yang, D., Park, E.-Y., & Jun, H. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2016.12.005 · Cited by 56
Self-citationGLP-1 (9–36) Amide Metabolite Suppression of Glucose Production in Isolated Mouse Hepatocytes
Tomás, E., Stanojevic, V., & Habener, J. F. (2010) · Hormone and Metabolic Research · doi:10.1055/s-0030-1253421 · Cited by 54
DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control
Bae, E. J. (2016) · Archives of Pharmacal Research · doi:10.1007/s12272-016-0813-x · Cited by 62
Liu, Y., Wei, R., & Hong, T. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i27.9090 · Cited by 55
Continuous measurement of enzymatic kinetics in droplet flow for point-of-care monitoring
Hassan, S.-U., Nightingale, A. M., & Niu, X. (2016) · The Analyst · doi:10.1039/c6an00620e · Cited by 53
Nurunnabi, M., Lee, S., Revuri, V., Hwang, Y. H., Kang, S. H., Lee, M., Cho, S., Cho, K.-J., Byun, Y., Bae, Y. H., et al. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.08.035 · Cited by 49
Self-citationGlucagon, GLP-1 and Thermogenesis
González-García, I., Milbank, E., Diéguez, C., López, M., & Contreras, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143445 · Cited by 49
Tiano, J. P., Tate, C. R., Yang, B. S., DiMarchi, R. D., & Mauvais‐Jarvis, F. (2015) · Scientific Reports · doi:10.1038/srep10211 · Cited by 50
Dusaulcy, R., Handgraaf, S., Skarupelova, S., Visentin, F., Vesin, C., Heddad-Masson, M., Reimann, F., Gribble, F. M., Philippé, J., & Gosmain, Y. (2016) · Endocrinology · doi:10.1210/en.2016-1433 · Cited by 56
Oxyntomodulin ameliorates glucose intolerance in mice fed a high-fat diet
Parlevliet, E. T., Heijboer, A. C., der Elst, J. P. S.-V., Havekes, L. M., Romijn, J. A., Pijl, H., & Corssmit, E. P. M. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00576.2007 · Cited by 49
Jakubowska, A., Roux, C. W. L., & Viljoen, A. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1942 · Cited by 45
Sztanek, F., Tóth, L. I., Pető, A., Hernyák, M., Diószegi, Á., & Harangi, M. (2024) · Biomedicines · doi:10.3390/biomedicines12061320 · Cited by 47
“Metabolic e ff ects mediated by GLP-1 include increased glucose uptake and glycogen production in skeletal muscle, as well as inhibition of gluconeogenesis in the liver [38] (Figure 4).”
BackgroundMagro, D. O., Cazzo, E., Kotze, P. G., Vasques, A. C. J., Martinez, C. A. R., Chaim, É. A., Geloneze, B., Pareja, J. C., & Coy, C. S. R. (2017) · Obesity Surgery · doi:10.1007/s11695-017-2851-y · Cited by 36
Pleiotropic effects of incretins
Gupta, V. (2012) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.94259 · Cited by 43
GLP-1 receptor independent pathways: emerging beneficial effects of GLP-1 breakdown products
Guglielmi, V., & Sbraccia, P. (2016) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-016-0352-y · Cited by 42
Chen, T., Reich, N. W., Bell, N., Finn, P. D., Rodriguez, D. J., Kohler, J. N., Kozuka, K., He, L., Spencer, A. G., Charmot, D., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00308 · Cited by 40
Microbially produced glucagon-like peptide 1 improves glucose tolerance in mice
Arora, T., Wegmann, U., Bobhate, A., Lee, Y. S., Greiner, T. U., Drucker, D. J., Narbad, A., & Bäckhed, F. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.06.006 · Cited by 36
Self-citationAntidiabetic exendin-4 activates apoptotic pathway and inhibits growth of breast cancer cells
Yaylalı, G. F., Dodurga, Y., Seçme, M., & Elmas, L. (2015) · Tumor Biology · doi:10.1007/s13277-015-4104-9 · Cited by 38
GLP-1 Therapy: Beyond Glucose Control
Hausenloy, D. J., & Yellon, D. M. (2008) · Circulation Heart Failure · doi:10.1161/circheartfailure.108.810887 · Cited by 39
CNS-targeting pharmacological interventions for the metabolic syndrome
Stemmer, K., Müller, T. D., DiMarchi, R. D., Pfluger, P. T., & Tschöp, M. H. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129195 · Cited by 36
Mechanisms of action of incretin receptor based dual- and tri-agonists in pancreatic islets
Folli, F. B., Finzi, G., Manfrini, R., Galli, A., Casiraghi, F., Centofanti, L., Berra, C., Fiorina, P., Davalli, A. M., Rosa, S. L., et al. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00236.2023 · Cited by 35
Elkhalifa, A. M. E., Nazar, M., Ali, S. I., Khursheed, I., Taifa, S., Ahmad Mir, M., Shah, I. H., Malik, M., Ramzan, Z., Ahad, S., et al. (2024) · Life · doi:10.3390/life14010099 · Cited by 31
Riedel, M. J., Gaddy, D. F., Asadi, A., Robbins, P. D., & Kieffer, T. J. (2009) · Gene Therapy · doi:10.1038/gt.2009.143 · Cited by 33
Long-Acting Release Microspheres Containing Novel GLP-1 Analog as an Antidiabetic System
Ruan, S., Gu, Y., Liu, B., Gao, H., Hu, X., Hao, H., Jin, L., & Cai, T. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00344 · Cited by 31
Fan, R., Kang, Z., He, L., Chan, J. C. N., & Xu, G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020443 · Cited by 34
GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis
Chen, Y., Xu, Y.-N., Ye, C.-Y., Feng, W., Zhou, Q., Yang, D., & Wang, M. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00836-9 · Cited by 34
Suzuki, T., Muramatsu, T., Morioka, K., Goda, T., & Mochizuki, K. (2015) · Nutrition · doi:10.1016/j.nut.2015.01.005 · Cited by 32
Garcia‐Soria, G., González-Gálvez, G., Argoud, G., Gerstman, M., Littlejohn, T. W., Schwartz, S. L., O'Farrell, A. M., Li, X., Cherrington, J. M., Bennett, C., et al. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00868.x · Cited by 29
PATEL, V. G., Joharapurkar, A. A., Dhanesha, N., Kshirsagar, S. G., Detroja, J., Patel, K. N., Gandhi, T. R., Patel, K. V., Bahekar, R. H., & Jain, M. R. (2013) · Pharmacological Reports · doi:10.1016/s1734-1140(13)71074-0 · Cited by 28
Plasmid DNA Nanoparticles for Nonviral Oral Gene Therapy
Shahriar, S. M. S., An, J. M., Hasan, M. N., Surwase, S. S., Kim, Y., Lee, D. Y., Cho, S., & Lee, Y.-K. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c00832 · Cited by 27
Self-citationMetabolic Hormones Modulate Macrophage Inflammatory Responses
Batty, M. J., Chabrier, G., Sheridan, A., & Gage, M. (2021) · Cancers · doi:10.3390/cancers13184661 · Cited by 29
Fang, H., Lın, L., Chen, J., Wu, J., Tian, H., & Chen, X. (2019) · Biomaterials Science · doi:10.1039/c9bm00039a · Cited by 27
Alpha-to-beta cell trans-differentiation for treatment of diabetes
Saleh, M. W., Gittes, G. K., & Prasadan, K. L. (2021) · Biochemical Society Transactions · doi:10.1042/bst20210244 · Cited by 31
Iida, A., Seino, Y., Fukami, A., Maekawa, R., Yabe, D., Shimizu, S., Kinoshita, K., Takagi, Y., Izumoto, T., Ogata, H., et al. (2016) · Diabetologia · doi:10.1007/s00125-016-3935-2 · Cited by 27
GLP-1 signaling is required for improvement of glucose tolerance by osteocalcin
Mizokami, A., Mukai, S., Gao, J., Kawakubo‐Yasukochi, T., Otani, T., Takeuchi, H., Jimi, E., & Hirata, M. (2019) · Journal of Endocrinology · doi:10.1530/joe-19-0288 · Cited by 27
Exenatide Activates the APPL1-AMPK-PPARαAxis to Prevent Diabetic Cardiomyocyte Apoptosis
XiaoTian, L., Wu, Q., XiaGuang, G., WuQuan, D., Chen, B., & ZiWen, L. (2015) · Journal of Diabetes Research · doi:10.1155/2016/4219735 · Cited by 27
Kim, P.-H., Lee, M., & Kim, S. W. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.06.010 · Cited by 26
Park, S., Hong, S. M., & Ahn, I. S. (2009) · Metabolism · doi:10.1016/j.metabol.2009.06.026 · Cited by 23
Therapeutic Potential of Lentivirus-Mediated Glucagon-Like Peptide-1 Gene Therapy for Diabetes
Tasyurek, H. M., Altunbaş, H., Balcı, M. K., Griffith, T. S., & Şanlıoğlu, S. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.180 · Cited by 24
Hu, C., Zhang, G., Sun, D., Han, H., & Hu, S. (2013) · Obesity Surgery · doi:10.1007/s11695-013-0976-1 · Cited by 24
Kim, Y.-K., Park, J.-H., Park, S.-H., Lim, B., Baek, W., Suh, S., Lim, J.-G., Ryu, G., & Song, D. (2010) · Cellular Physiology and Biochemistry · doi:10.1159/000276555 · Cited by 25
Vincent, R. K., Williams, D. M., & Evans, M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14196 · Cited by 22
GLP-1-mediated gene therapy approaches for diabetes treatment
Tasyurek, H. M., Altunbaş, H., Canatan, H., Griffith, T. S., & Şanlıoğlu, S. (2014) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2014.7 · Cited by 24
Wang, Yu, Zhang, Floyd, Z. E., Lian, Cefalu, & Boudreau (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s30887 · Cited by 22
Glucagon-Like Peptide-1 Gene Therapy
Rowzee, A. M., Cawley, N. X., Chiorini, J. A., & Pasquale, G. D. (2011) · Experimental Diabetes Research · doi:10.1155/2011/601047 · Cited by 24
Lee, Y., Kwon, M. K., Kang, E. S., Park, Y. M., Choi, S. H., Ahn, C. W., Kim, K., Park, C. W., Soo, B., Kim, S. W., et al. (2007) · The Journal of Gene Medicine · doi:10.1002/jgm.1153 · Cited by 20
Self-citationTreatment of non-alcoholic fatty liver disease with focus on emerging drugs
Marchesini, G., Moscatiello, S., Agostini, F., Villanova, N., & Festi, D. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.531700 · Cited by 22
Gene doping: gene delivery for olympic victory
Gould, D. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12010 · Cited by 21
Park, S., Hong, S. M., Ahn, I. S., Kim, Y. J., & Lee, J. B. (2009) · Bioscience Biotechnology and Biochemistry · doi:10.1271/bbb.90276 · Cited by 20
Choi, S. H., & Lee, H. C. (2010) · Gene Therapy · doi:10.1038/gt.2010.119 · Cited by 21
Sakai, Y., Chen, G., Ni, Y., Zhuge, F., Xu, L., Nagata, N., Kaneko, S., Ota, T., & Nagashimada, M. (2020) · Endocrinology · doi:10.1210/endocr/bqaa139 · Cited by 19
Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review
Teshome, G., Ambachew, S., Fasil, A., & Abebe, M. (2020) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s265631 · Cited by 20
Han, F., Ning, M., Cao, H., Ye, Y., Feng, Y., Leng, Y., & Shen, J. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112619 · Cited by 17
Hepatic electrical stimulation reduces blood glucose in diabetic rats
Chen, J., Pasricha, P. J., Yin, J., Li, L., & Chen, J. D. Z. (2010) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2010.01556.x · Cited by 18
Pasquale, G. D., Dicembrini, I., Raimondi, L., Pagano, C., Egan, J. M., Cozzi, A., Cinci, L., Loreto, A., Manni, M. E., Berretti, S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040074 · Cited by 18
Gao, H., Zhao, Q., Song, Z., Yang, Z., Wu, Y., Tang, S., Alahdal, M., Zhang, Y., & Jin, L. (2017) · The FASEB Journal · doi:10.1096/fj.201700002r · Cited by 15
Lipoprotein effects of incretin analogs and dipeptidyl peptidase 4 inhibitors
Zhong, J., Maiseyeu, A., & Rajagopalan, S. (2015) · Clinical Lipidology · doi:10.2217/clp.14.59 · Cited by 16
Vitamin C and E chronic supplementation differentially affect hepatic insulin signaling in rats
Ali, M. A., Eid, R. M. H. M., & Hanafi, M. Y. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.12.039 · Cited by 15
Zhou, R., Lin, Z., Jiang, C., Gong, J., Chen, L., Guo, Y., & Shen, X. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.47 · Cited by 15
Wang, Y., Li, M., Guo, J., Kang, S., Huang, K., & Tong, T. (2023) · Food Frontiers · doi:10.1002/fft2.301 · Cited by 14
Barakat, G. M., Moustafa, M. E., Khalifeh, I. M., Hodroj, M. H., Bikhazi, A. B., & Rizk, S. E. (2016) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-017-0565-1 · Cited by 14
Metadata
- Authors
- Lee, Y.-S., Shin, S., Shigihara, T., Hahm, E., Liu, M.-J., Han, J., Yoon, J.-W., & Jun, H.-S.
- Affiliations
- Rosalind Franklin University of Medicine and Science (US)
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2007-06-01
- Volume
- 56
- Issue
- 6
- Pages
- 1671-1679
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2096880961
- Cited by
- 158
- References
- 50
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 7 · 2023: 4 · 2022: 2 · 2021: 5 · 2020: 11 · 2019: 10 · 2018: 8 · 2017: 8 · 2016: 10 · 2015: 11 · 2014: 7 · 2013: 7 · 2012: 12
- FWCI
- 8.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- glucagon-like peptide-1, gene therapy, adenoviral vector, ob/ob mice, obesity, type 2 diabetes, diabetes remission, insulin sensitivity, hepatic gluconeogenesis, insulin signaling, IRS-1, beta-cell function, glucose tolerance, insulin-stimulated glucose uptake, phosphoenolpyruvate carboxykinase, glucose-6-phosphatase, fatty acid synthase
- MeSH terms
- Animals, Diabetes Mellitus, Experimental, Gluconeogenesis, Glucose Tolerance Test, Insulin, Liver, Mice, Obese, RNA, Messenger, Genetic Therapy, Reverse Transcriptase Polymerase Chain Reaction, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.